Ventyx Biosciences: Financial Report Reveals Growth Challenges by Terry Bingman 28.03.2024 Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...
Medicxi Launches Alys Pharmaceuticals in $100m Seed Funding by Mark Eisenberg 19.02.2024 Medicxi launches Alys Pharmaceuticals with $100m funding to develop groundbreaking therapies in immunodermatology. The company aims to address unmet needs ...